What happened
Hanall Biopharma filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$30.7M (+8.8% year on year), operating profit of US$3.88M (+388.5% year on year) and a net loss of US$13.3M (from a profit a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$30.7M |
|---|---|
| Revenue vs a year earlier | +8.8% |
| Operating profit | US$3.88M |
| Net income | −US$13.3M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-07-29, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260729800663 → open original filing |
Source: DART. Information only, not investment advice.